胰腺癌干细胞作为胰腺癌治疗靶点的研究进展  

Research progresses of pancreatic cancer stem cells as therapeutic targets of pancreatic cancer

作　　者：刘旭 董勤(综述)[1] 王震侠[1] 赵建国(审校)[1] LIU Xu;DONG Qin;WANG Zhenxia;ZHAO Jianguo(Affiliated Hospital of Inner Mongolia Medical University,Huhehot,Inner Mongolia 010050,China)

机构地区：[1]内蒙古医科大学附属医院肝胆胰脾外科,呼和浩特010050

出　　处：《重庆医学》2021年第7期1212-1216,共5页Chongqing medicine

基　　金：国家自然科学基金项目(81560384);内蒙古自治区科技计划项目(2019GG085);内蒙古自然科学基金项目(2019MS08025);内蒙古自治区草原英才创新人才团队项目(DC1900003486)。

摘　　要：胰腺导管腺癌(PDAC)是胰腺癌最常见的类型,其总体生存期为6~12个月,5年生存率低于7%,这主要是由于该肿瘤的早期局部侵袭和转移,以及肿瘤内存在的一种高度可塑性的肿瘤干细胞(CSCs)。CSCs是肿瘤内具有干细胞特性的一个小亚群,在PDAC中,占胰腺所有肿瘤细胞的不到1%,但其可使PDAC产生化疗耐药、增强致瘤能力,并且还和肿瘤的发生、发展、转移有着密切的联系。越来越多的证据支持CSCs作为PDAC诱导细胞的存在,并且正在努力开发针对这些细胞的治疗策略。该文总结了目前对胰腺癌干细胞(PCSC)的认识及近年来的研究进展,概述以PCSC为靶点治疗PDAC的研究现状。Pancreatic ductal adenocarcinoma(PDAC)is the most common type of pancreatic cancer,with an overall survival of 6-12 months and a 5-year survival rate of less than 7%,which is mainly due to the early local invasion and metastasis of the tumor,and a kind of highly plastic tumor stem cells(CSCs)existing in the tumor.CSCs are a small subset of stem cells with tumor characteristics.In PDAC,they account for less than 1%of all tumor cells in the pancreas,but they can make PDAC resistant to chemotherapy,enhance tumorigenicity,and also closely related to the occurrence,development and metastasis of tumors.More and more evidence supports the existence of CSCs as PDAC induced cells,and the efforts are being made to develop therapeutic strategies for these cells.This article summarizes the current understanding of pancreatic cancer stem cells(PCSC)and the research progress in recent years,and also ummarizes the research status quo of PCSC as a target in the treatment of PDAC.

关 键 词：肿瘤干细胞 胰腺导管腺癌 靶向治疗 

分 类 号：R657.5[医药卫生—外科学]